iodine i 131 mip 1095

Drug Overview

The medication known as iodine i 131 mip 1095 is a highly specialized, experimental medical treatment used in advanced cancer care. It is not a standard, everyday medicine. Instead, it belongs to an advanced class of treatments known as Targeted Therapies or “Smart Drugs.” Doctors and researchers are actively studying this drug to see how well it can fight severe forms of prostate cancer that have stopped responding to traditional treatments.

Here are the key details about this medication:

• Generic Name: iodine I-131 MIP-1095 (often shortened to 131I-MIP-1095 or 131I-PSMA-1095).
• US Brand Names: None yet. It is an investigational drug, meaning it does not have a commercial brand name.
• Drug Class: Radiopharmaceutical / Targeted Radioligand Therapy.
• Route of Administration: Intravenous (IV) injection.
• FDA Approval Status: Currently investigational. It is not approved by the FDA for standard public use. It is only available to patients who are participating in carefully monitored clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Iodine I-131 MIP-1095 is a “Smart Drug” targeting prostate cancer cells. MIP-1095 binds PSMA receptors (the lock), enters the cell, and delivers radioactive iodine-131, which damages DNA, killing the tumor while sparing healthy tissue.

FDA-Approved Clinical Indications

Because iodine I-131 MIP-1095 is an investigational agent, it does not currently have official FDA-approved indications for routine medical practice. However, it is being extensively studied in approved clinical trials (such as the ARROW trial) for the following specific purposes:

Oncological Uses (In Clinical Trials):

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Used to treat prostate cancer that has spread to other parts of the body (bones or soft tissues) and continues to grow even when testosterone levels in the body are deeply lowered.
• Treatment-Resistant Tumors: Used for patients whose cancer has progressed after trying standard hormone therapies (like abiraterone or enzalutamide) or standard chemotherapy.

Non-oncological Uses:

• There are currently no non-cancer-related uses for this drug. It is strictly being studied for oncology.

Dosage and Administration Protocols

Because this is a radioactive therapeutic agent, it is given in a specialized nuclear medicine department, not as a daily pill. The dose is carefully calculated by a nuclear medicine physician based on the patient’s specific body metrics and prior test results.

Clinical Efficacy and Research Results

Recent clinical studies (conducted between 2020 and 2025) have shown promising results for iodine I-131 MIP-1095, particularly for patients who have run out of other treatment options.

• Tumor Marker Reduction: In Phase 1 and Phase 2 trials, researchers measured the Prostate-Specific Antigen (PSA), a blood marker that shows how active the prostate cancer is. Studies show that between 66% and 70.6% of patients experienced a significant PSA drop of 50% or more after receiving the therapy, indicating that the drug successfully shrank or slowed the tumors.
• Survival Rates: A 2024 Phase 2 clinical trial evaluating heavily pre-treated men with metastatic castration-resistant prostate cancer showed meaningful survival benefits. The median Overall Survival (OS) for patients receiving this drug was 10.3 months. Additionally, the median Progression-Free Survival (PFS)—the amount of time the patient lived without the disease getting worse—was 5.4 months.
• Overall Impact: While the therapy is not a cure, these numerical results prove that this targeted radiation can effectively reduce tumor burden and buy valuable time for patients facing aggressive, late-stage disease.

Safety Profile and Side Effects

Because iodine I-131 MIP-1095 delivers radiation directly to cells, it can cause specific side effects, mostly related to where the drug travels in the body before being cleared.

Black Box Warning

There is no FDA Black Box Warning for this drug at this time, as it is still an investigational agent in clinical trials.

Common Side Effects (>10%)

• Xerostomia (Dry Mouth): The most common side effect. The salivary glands can accidentally absorb some of the drug, leading to decreased saliva production and temporary or long-term dry mouth.
• Hematologic Toxicity (Blood Count Drops): Mild to moderate drops in red blood cells (anemia), white blood cells (leukopenia), and blood-clotting cells (thrombocytopenia).
• Fatigue: Feeling unusually tired or weak for several weeks after the infusion.
• Mild Nausea: An upset stomach shortly after the treatment.

Serious Adverse Events

• Severe Bone Marrow Suppression: In some cases, blood cell counts can drop to dangerously low levels (Grade 3 or higher). This can increase the risk of severe, life-threatening infections or major bleeding events.
• Kidney or Thyroid Issues (Rare): Although rare, the radiation can irritate the kidneys as it leaves the body, or affect the thyroid gland if it absorbs free radioactive iodine.

Management Strategies

• For Dry Mouth: During the infusion and shortly after, patients are often given lemon juice, sour candies, or ice packs to place on their cheeks. This helps constrict blood vessels and encourages saliva flow, which washes the radiation out of the salivary glands quickly.
• For Blood Counts: Doctors will perform frequent blood tests. If counts drop too low, the patient may receive blood transfusions, or the doctor will lower the dose for the next treatment cycle.
• For Thyroid Protection: Patients are usually given a special medication (like sodium perchlorate or iodine drops) before the treatment. This fills up the thyroid with safe, normal iodine so it cannot absorb the radioactive iodine.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

While iodine I-131 MIP-1095 is primarily a cancer-destroying agent, current research is exploring its use alongside treatments that affect cell regeneration and DNA repair. Scientists are testing this drug in combination with “radiosensitizers” (like PARP inhibitors). These are medications that stop cancer cells from repairing their own DNA. By combining the radiation from 131I-MIP-1095 with drugs that block cellular repair, doctors hope to permanently destroy aggressive cancer stem cells that normally survive standard treatments and cause the cancer to regrow.

Patient Management and Practical Recommendations

To ensure the treatment works well and is handled safely, patients must follow strict rules before, during, and after receiving the medication.

Pre-treatment Tests to be Performed

• PSMA PET Scan: A special imaging scan must be done first to confirm that the patient’s tumors actually have the PSMA “locks” on them. If the tumors do not have PSMA, the drug will not work.
• Extensive Blood Work: A Complete Blood Count (CBC) is required to make sure the patient’s bone marrow is healthy enough to handle the radiation.
• Kidney and Liver Tests: To ensure the body can safely process and clear the drug.

Precautions During Treatment

• Patients will receive IV fluids before and after the medicine to protect the kidneys.
• Because the patient becomes temporarily radioactive, they must stay in a specially lined hospital room for several days (usually 5 to 8 days) until their radiation levels drop to a safe limit, per local radiation protection laws.

“Do’s and Don’ts” List

• DO drink large amounts of water and empty your bladder frequently for several days after treatment. This helps flush the radioactive waste out of your body.
• DO take all prescribed thyroid-protecting drops exactly as the doctor orders them.
• DO practice excellent hygiene, such as flushing the toilet twice after use, to prevent exposing family members to radiation.
• DON’T have close physical contact (like hugging or sharing a bed) with pregnant women, babies, or young children for the specific number of days your doctor tells you after leaving the hospital.
• DON’T ignore any signs of fever, chills, or unusual bruising when you go home. Contact your care team immediately, as this could mean your blood counts are too low.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Iodine I-131 MIP-1095 is an investigational therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and your eligibility for participating in clinical trials.